Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 691 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Corticosteroid Clear all

Conditions: Asthma
Interventions: Ciclesonide (XRP1526); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 84
States / cities: Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more

Conditions: Chronic Inflammatory Skin Diseases
Interventions: Video, Standard Script; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Seasonal Allergic Rhinitis
Interventions: Bepotastine besilate formulation, Fluticasone propionate, Bepotastine besilate-fluticasone propionate, Placebo Comparator; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Irvine, California

Conditions: Primary Immune Thrombocytopenia (ITP)
Interventions: Ianalumab, Placebo, Corticosteroids; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 20
States / cities: Yuma, Arizona • Clovis, California • Fountain Valley, California + 16 more

Conditions: Adrenocortical Carcinoma, Adrenal Cancer, ACC
Interventions: ATR-101; Drug
Lead sponsor: Millendo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Tampa, Florida • Bethesda, Maryland • Ann Arbor, Michigan + 1 more

Conditions: Carcinoma, Adrenal Cortical
Interventions: Etoposide, Doxorubicin, Cisplatin, Streptozotocin, Mitotane; Drug
Lead sponsor: Collaborative Group for Adrenocortical Carcinoma Treatment; Other
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Conditions: Cutaneous Lupus
Interventions: 532nm laser, 1064nm laser, Topical corticosteroid; Device · Drug
Lead sponsor: David Weinstein; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Hypoxemia, Severe Acute Respiratory Syndrome
Interventions: Corticosteroid; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Ulcerative Colitis
Interventions: Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more

Conditions: Bursitis
Interventions: Trochanter bursa injections, Ultrasound; Procedure · Device
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Asthma
Interventions: lebrikizumab, placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 70
States / cities: Pell City, Alabama • Scottsdale, Arizona • Tucson, Arizona + 63 more

Conditions: Uveitis, Intermediate, Uveitis, Posterior
Interventions: Dexamethasone pellet; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma, Lung Adenocarcinoma, Bladder Urothelial Carcinoma, Stomach Adenocarcinoma, Breast Cancer Invasive, Ovarian Carcinoma, Cervical Cancer, Non Small Cell Lung Cancer, Gastric Cancer, Biliary Tract Cancer, Melanoma, Pancreas Cancer, MDM2 Gene Amplification, Testicular Germ Cell Tumor, Adrenocortical Carcinoma
Interventions: RAIN-32; Drug
Lead sponsor: Rain Oncology Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 14
States / cities: Palo Alto, California • Fort Myers, Florida • St. Petersburg, Florida + 10 more

Conditions: Asthma
Interventions: Fluticasone furoate 50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Long Beach, California • Los Angeles, California • Newport Beach, California + 7 more

Conditions: Asthma
Interventions: QGE031, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Birmingham, Alabama • Kingwood, Texas • Plano, Texas

Conditions: Disc Herniation, Lumbosacral Radiculopathy
Interventions: CT-guided corticosteroid+ bupivicaine, Standard medical care; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 21 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Osteo Arthritis Knee
Interventions: Amniotic Fluid Injection, Standard of Care; Biological · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hydrocortisone, Depression, Healthy Volunteers
Interventions: Hydrocortisone Oral, Placebo Oral Tablet; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Asthma
Interventions: IPL512,602 20 mg once daily, IPL512,602 Matching Placebo once daily; Drug
Lead sponsor: Inflazyme Pharmaceuticals Ltd; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Long Beach, California • Los Angeles, California • San Diego, California + 5 more

Conditions: Osteoporosis
Interventions: Zoledronic Acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 802 participants
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Birmingham, Alabama • Gainesville, Georgia • Cumberland, Maryland + 3 more

Conditions: Psoriasis
Interventions: Calcitriol ointment, Clobetasol spray; Drug
Lead sponsor: Emer, Jason, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Kidney Transplantation
Interventions: Rabbit Antithymocyte Globulin, Velcade, Rituxan; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Asthma
Interventions: Placebo once daily, QAW039 150 mg once daily, QAW039 450 mg once daily; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Newport Beach, California • Westminster, California • Winter Park, Florida + 6 more

Search by objective public record fields.

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

Video-Based Education for Dermatology Patients on Systemic Corticosteroids

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma

Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)

Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone

Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Comparison of Ultrasound Guided Versus Blind Corticosteroid Injection for Trochanteric Bursitis

A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

Study of the Effectiveness of Ozurdex for the Control of Uveitis

Milademetan in Advanced/Metastatic Solid Tumors

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

CT Guided Injection for Low Back Radiculopathy: A Randomized Clinical Trial

pAF for the Treatment of Osteoarthritis

Exploring the Effects of Corticosteroids on the Human Hippocampus

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis

Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis

Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients